Corcept Therapeutics CORT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's accounts payable?
- Corcept Therapeutics (CORT) reported accounts payable of $33.31M in Q1 2026.
- How has Corcept Therapeutics's accounts payable changed year-over-year?
- Corcept Therapeutics's accounts payable increased by 19.2% year-over-year, from $27.95M to $33.31M.
- What is the long-term trend for Corcept Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accounts payable has grown at a 30.8% compound annual growth rate (CAGR), from $10.55M to $40.44M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services received.
- How do you interpret accounts payable?
- An increase may indicate improved cash flow management or delayed payments, while a decrease suggests faster settlement of obligations.
- How does accounts payable compare across companies?
- Standard across all industries; peers typically maintain levels proportional to their operating expenses and procurement cycles.